SLC5A2 and hydrops fetalis: In the EMPA-RESPNSE-AHF trial (the first study to evaluate the effects and safety of SGLT2 inhibitors in acute decompensated HF), despite the small sample size, these agents reduced the risk of rehospitalization for HF or death within 60 days, vs. placebo (131).